FDA label 3c1af002-56c9-4f89-96f9-425921e5d579

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
9f7f2a33-b3fc-44ee-960a-a9e4db7673ea
SPL ID
3c1af002-56c9-4f89-96f9-425921e5d579
Version
4
Effective date
2013-06-07
Source export date
2026-11-13
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/4245fd4310917b72c4a58c789d30a0b365e492ef46f48e107e3c3e16139b0499/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:24:31

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric malignancy ( 5.1 ) Anaphylaxis has been reported with use of intravenous pantoprazole ( 5.2 ) Thrombophlebitis is associated with the administration of intravenous pantoprazole ( 5.3 ) Zinc supplementation should be considered in patients treated with Pantoprazole Sodium for Injection who are prone to zinc deficiency. Caution should be used when other EDTA containing products are also co-administered intravenously ( 5.4 ) PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea ( 5.5 ) Bone Fracture: PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine after long term and multiple daily dose. ( 5.6 ) Hypomagnesemia has been reported rarely with prolonged treatment with PPIs ( 5.8 ) 5.1 Implications of Symptomatic Response Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric malignancy. 5.2 Hypersensitivity and Severe Skin Reactions Anaphylaxis and other serious reactions such as erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN) has been reported with use of intravenous pantoprazole. These may require emergency medical treatment [see Adverse Reactions ( 6.2 )] . 5.3 Injection Site Reactions Thrombophlebitis was associated with the administration of intravenous pantoprazole. 5.4 Potential for Exacerbation of Zinc Deficiency Pantoprazole Sodium for Injection contains edetate disodium (the salt form of EDTA), a chelator of metal ions including zinc. Therefore, zinc supplementation should be considered in patients treated with Pantoprazole Sodium for Injection who are prone to zinc deficiency. Caution should be used when other EDTA containing products are also co-administered intravenously. 5.5 Clostridium Difficile associated diarrhea Published observational studies suggest that PPI therapy like Pantoprazole Sodium for Injection may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. [ see Adverse Reactions ( 6.2 ) ]. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. 5.6 Bone Fracture Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines. (See Dosage and Administration and Adverse Reactions sections). 5.7 Hepatic Effects Mild, transient transaminase elevations have been observed in clinical studies. The clinical significance of this finding in a large population of subjects administered intravenous pantoprazole is unknown. (See Adverse Reactions ). 5.8 Hypomagnesemia Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, and in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )]. 5.9 Interference with Urine Screen for THC May produce false-positive urine screen for THC (tetrahydrocannabinol) [see Drug Interactions ( 7.4 )] . 5.10 Concomitant use of Pantoprazole Sodium with Methotrexate Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients. [ see Drug Interactions ( 7.6 ) ]

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS Worldwide, approximately 80,500 patients have been treated with pantoprazole in clinical trials involving various dosages and duration of treatment. The most frequently occurring adverse reactions are as follows: For adult use ( > 2 %) are headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Akorn, Inc. at 1-800-932-5676 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Gastroesophageal Reflux Disease (GERD) Safety in nine randomized comparative US clinical trials in patients with GERD included 1,473 patients on oral pantoprazole (20 mg or 40 mg), 299 patients on an H 2 -receptor antagonist, 46 patients on another proton pump inhibitor, and 82 patients on placebo. The most frequently occurring adverse reactions are listed in Table 1 . The number of patients treated in comparative studies with I.V. pantoprazole is limited; however, the adverse reactions seen were similar to those seen in the oral studies. Thrombophlebitis was the only new adverse reaction identified with I.V. pantoprazole. Table 1: Adverse Reactions Reported in Clinical Trials of Adult Patients with GERD at a Frequency of > 2% Pantoprazole (n=1473) % Comparators (n=345) % Placebo (n=82) % Headache 12.2 12.8 8.5 Diarrhea 8.8 9.6 4.9 Nausea 7.0 5.2 9.8 Abdominal pain 6.2 4.1 6.1 Vomiting 4.3 3.5 2.4 Flatulence 3.9 2.9 3.7 Dizziness 3.0 2.9 1.2 Arthralgia 2.8 1.4 1.2 Additional adverse reactions that were reported for pantoprazole sodium in US clinical trials with a frequency of ≤ 2% are listed below by body system: Body as a Whole: allergic reaction, fever, photosensitivity reaction, facial edema, thrombophlebitis (I.V. only) Gastrointestinal: constipation, dry mouth, hepatitis Hematologic: leukopenia (reported in ex-US clinical trials only), thrombocytopenia Metabolic/Nutritional: elevated CPK (creatine phosphokinase), generalized edema, elevated triglycerides, liver function tests abnormal Musculoskeletal: myalgia Nervous: depression, vertigo Skin and Appendages: urticaria, rash, pruritus Special Senses: blurred vision Zollinger-Ellison Syndrome In clinical studies of Zollinger-Ellison Syndrome, adverse reactions reported in 35 patients taking pantoprazole 80 mg /day to 240 mg /day for up to 2 years were similar to those reported in adult patients with GERD. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of pantoprazole sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions are listed below by body system: General Disorders and Administration Conditions: asthenia, fatigue, malaise Immune System Disorders: anaphylaxis (including anaphylactic shock) Investigations: weight changes Skin and Subcutaneous Tissue Disorders: severe dermatologic reactions (some fatal), including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN), and angioedema (Quincke's edema) Musculoskeletal Disorders: rhabdomyolysis, bone fracture Renal and Urinary Disorders: interstitial nephritis Hepatobiliary Disorders: hepatocellular damage leading to jaundice and hepatic failure Psychiatric Disorders: hallucinations, confusion, insomnia, somnolence Metabolism and Nutritional Disorders: hyponatremia , hypomagnesemia Infections and Infestations: Clostridium difficile associated diarrhea

adverse reactions table

<table ID="t1" width="100%"> <caption>Table 1: Adverse Reactions Reported in Clinical Trials of Adult Patients with GERD at a Frequency of &gt; 2% </caption> <col width="28.175%" align="left"/> <col width="27.275%" align="left"/> <col width="27.275%" align="left"/> <col width="17.275%" align="left"/> <tbody> <tr> <td align="left" valign="top" styleCode="Toprule Botrule"/> <td align="center" valign="top" styleCode="Toprule Botrule"> <content styleCode="bold">Pantoprazole</content> <content styleCode="bold">(n=1473)</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Toprule Botrule"> <content styleCode="bold">Comparators</content> <content styleCode="bold">(n=345)</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Toprule Botrule"> <content styleCode="bold">Placebo</content> <content styleCode="bold">(n=82)</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td align="left" valign="top">Headache </td> <td align="center" valign="top">12.2 </td> <td align="center" valign="top">12.8 </td> <td align="center" valign="top">8.5 </td> </tr> <tr> <td align="left" valign="top">Diarrhea </td> <td align="center" valign="top">8.8 </td> <td align="center" valign="top">9.6 </td> <td align="center" valign="top">4.9 </td> </tr> <tr> <td align="left" valign="top">Nausea </td> <td align="center" valign="top">7.0 </td> <td align="center" valign="top">5.2 </td> <td align="center" valign="top">9.8 </td> </tr> <tr> <td align="left" valign="top">Abdominal pain </td> <td align="center" valign="top">6.2 </td> <td align="center" valign="top">4.1 </td> <td align="center" valign="top">6.1 </td> </tr> <tr> <td align="left" valign="top">Vomiting </td> <td align="center" valign="top">4.3 </td> <td align="center" valign="top">3.5 </td> <td align="center" valign="top">2.4 </td> </tr> <tr> <td align="left" valign="top">Flatulence </td> <td align="center" valign="top">3.9 </td> <td align="center" valign="top">2.9 </td> <td align="center" valign="top">3.7 </td> </tr> <tr> <td align="left" valign="top">Dizziness </td> <td align="center" valign="top">3.0 </td> <td align="center" valign="top">2.9 </td> <td align="center" valign="top">1.2 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule">Arthralgia </td> <td align="center" valign="top" styleCode="Botrule">2.8 </td> <td align="center" valign="top" styleCode="Botrule">1.4 </td> <td align="center" valign="top" styleCode="Botrule">1.2 </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.